BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30148988)

  • 21. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
    Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
    Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRN2 is a non-canonical melanoma tumor-suppressor.
    Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
    Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations of PTEN in human melanoma.
    Aguissa-Touré AH; Li G
    Cell Mol Life Sci; 2012 May; 69(9):1475-91. PubMed ID: 22076652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma.
    Saldanha G; Potter L; Lee YS; Watson S; Shendge P; Pringle JH
    Melanoma Res; 2016 Feb; 26(1):21-8. PubMed ID: 26731559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
    Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN.
    Mao XH; Chen M; Wang Y; Cui PG; Liu SB; Xu ZY
    Mol Carcinog; 2017 Mar; 56(3):886-894. PubMed ID: 27533779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
    Namiki T; Yaguchi T; Nakamura K; Valencia JC; Coelho SG; Yin L; Kawaguchi M; Vieira WD; Kaneko Y; Tanemura A; Katayama I; Yokozeki H; Kawakami Y; Hearing VJ
    Cancer Res; 2015 Jul; 75(13):2708-15. PubMed ID: 25832654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
    Zhou XP; Gimm O; Hampel H; Niemann T; Walker MJ; Eng C
    Am J Pathol; 2000 Oct; 157(4):1123-8. PubMed ID: 11021816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of PTEN status in Sezary syndrome.
    Cristofoletti C; Picchio MC; Lazzeri C; Tocco V; Pagani E; Bresin A; Mancini B; Passarelli F; Facchiano A; Scala E; Lombardo GA; Cantonetti M; Caprini E; Russo G; Narducci MG
    Blood; 2013 Nov; 122(20):3511-20. PubMed ID: 24062018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.
    Foster JS; Fish LM; Phipps JE; Bruker CT; Lewis JM; Bell JL; Solomon A; Kestler DP
    BMC Cancer; 2013 May; 13():227. PubMed ID: 23648148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
    Paraiso KH; Xiang Y; Rebecca VW; Abel EV; Chen YA; Munko AC; Wood E; Fedorenko IV; Sondak VK; Anderson AR; Ribas A; Palma MD; Nathanson KL; Koomen JM; Messina JL; Smalley KS
    Cancer Res; 2011 Apr; 71(7):2750-60. PubMed ID: 21317224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis.
    Yamamoto Y; Matsusaka K; Fukuyo M; Rahmutulla B; Matsue H; Kaneda A
    Cancer Med; 2020 Oct; 9(19):7194-7204. PubMed ID: 32406600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
    Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
    Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and genetic diversity in the metastatic process of melanoma.
    Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
    J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
    Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
    Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
    Nogueira C; Kim KH; Sung H; Paraiso KH; Dannenberg JH; Bosenberg M; Chin L; Kim M
    Oncogene; 2010 Nov; 29(47):6222-32. PubMed ID: 20711233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN/MMAC1 expression in melanoma resection specimens.
    Deichmann M; Thome M; Benner A; Egner U; Hartschuh W; Näher H
    Br J Cancer; 2002 Dec; 87(12):1431-6. PubMed ID: 12454773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.